Astellas Usa Foundation

The Astellas Global Health Foundation — legally registered as the Astellas USA Foundation (EIN: 52-1820099) — is a highly selective, invitation-driven corporate foundation anchored to its parent pharmaceutical company's global health mission. With $30.9 million in assets as of fiscal year 2024 and a historical average of approximately $2.4 million in annual grantmaking (calculated across nine fiscal years from 2011–2022), the foundation funds a concentrated portfolio of 3–6 organizations per grant cycle, favoring deep, multi-year partnerships over single-year transactional grants.

First-time applicants face a fundamental structural barrier: the foundation does not accept unsolicited proposals or letters of inquiry under any circumstances. All organizations must be identified through an internal Request for Proposal (RFP) process and issued a formal invitation before an application can be submitted through the online portal. This means relationship-building and sustained visibility within global health networks — specifically those connected to Astellas Pharma's philanthropic agenda — is the only legitimate pathway to funding consideration.

The foundation's organizational preferences are instructive. Top grantees include Indiana University (AMPATH Kenya), Sightsavers, Amref Health Africa, Americares, and USA for UNHCR — all large, internationally recognized NGOs with multi-decade track records. Individual grant disbursements average $460,000, and the five top grantees each received two documented awards for cumulative totals averaging $920,000 per grantee relationship. This signals a strong preference for proven institutions with robust monitoring and evaluation capacity. The foundation does not cultivate emerging or startup organizations.

The geographic filter is strict: programs must operate in low- and middle-income countries where Astellas Pharma holds no commercial pharmaceutical presence. This excludes programming in major markets like Japan, the US, and Western Europe, but opens significant opportunity in Sub-Saharan Africa (Kenya, Senegal, Uganda), Latin America (Peru), and the Middle East (Yemen). Organizations with established program infrastructure in these regions are the most competitive candidates.

Strategically, the best entry point for organizations not yet in the portfolio is to cultivate visibility through shared conference participation (WHO World Health Assembly, UN General Assembly side events, International AIDS Conference), partner with current grantees in multi-organization consortia, and build name recognition with Astellas Pharma's corporate sustainability and global health teams — the staff pipeline that feeds the foundation's internal RFP nominee list. The foundation's explicit alignment with UN SDG Goal 3 (healthy lives for all) provides the most effective framing language for positioning any program.

The foundation's grantmaking exhibits a recognizable biennial rhythm across its IRS 990 filing history. Annual giving has fluctuated between $1.4 million (2014) and $4.3 million (2022) over the past decade, with peak disbursement years occurring roughly every two to three years: $3.4M in 2013, $3.8M in 2019, and $4.3M in 2022 — the highest on record. Lower-giving years ($1.5M–$2.1M) reflect the natural disbursement structure of multi-year grants paid in tranches across 2–3 year project timelines, not reductions in the endowment's commitment to grantmaking.

Grant size analysis from the foundation's 10 documented top-grantee disbursements ($4.6M total) puts the mean at $460,000 per individual grant. The foundation's own reported typical grant range is $300,000–$450,000, with a reported median of $400,000. In practice, the January 2024 grant cycle reveals a wider operating range: a floor of $345,000 (International Medical Corps, Yemen, one year) through $690,000 mid-tier awards (Plan International Peru; Americares; USA for UNHCR) up to $1.07 million for multi-year AMPATH Kenya, Sightsavers, and Amref Health Africa relationships, and a $1.6 million ceiling for the PATH HIV/AIDS three-year award — the largest single grant the foundation has publicly announced.

Program area concentration falls across three domains. Neglected tropical and communicable diseases — including HIV/AIDS (funded for the first time in 2024), tuberculosis, and malaria — receive an estimated 40–50% of recent grantmaking, led by PATH ($1.6M) and AMPATH Kenya ($1.07M). Children's health and vision/community health systems account for approximately 25–35%, including Amref Health Africa's Senegal child health programming and Sightsavers' NTD work (each $1.07M). Disaster preparedness and humanitarian health response represents 15–25%, covering Americares, USA for UNHCR, and Plan International Peru ($690K each).

Geographically, Sub-Saharan Africa dominates the portfolio (Kenya, Senegal, Uganda), with Latin America (Peru) and the Middle East (Yemen) serving as secondary geographies. The foundation explicitly excludes research grants, medical education, individual scholarships, capital campaigns, administrative overhead exceeding 15% of program costs, and organizations operating in OFAC-sanctioned countries.

Comparing Astellas Global Health Foundation to peer corporate pharma foundations reveals a mid-tier funder with a uniquely narrow geographic and disease-area mandate. Peer asset and giving figures below are approximate, drawn from publicly available 990 filings and foundation reports; use them for directional comparison only.

Astellas Global Health Foundation is mid-tier by both assets and giving volume, but distinguishes itself through its exclusive LMIC geographic mandate — the only foundation in this peer set that explicitly excludes countries where its parent company operates commercially. Unlike the BMS Foundation or Merck Company Foundation, which fund significant domestic US programming alongside global work, Astellas targets solely international programming in underserved regions with no commercial overlap. All five foundations operate primarily invitation-based models, meaning organizational visibility and relationship capital with corporate philanthropy staff — not grant-writing quality alone — is the primary competitive differentiator across the peer group.

The foundation's most recent publicly documented grant cycle was announced on January 25, 2024, distributing $2.6 million across three organizations. International Medical Corps received $345,000 over one year to strengthen healthcare infrastructure in 10 vulnerable communities in Yemen, with an estimated reach of 60,000 beneficiaries. PATH received the cycle's flagship award — over $1.6 million across three years, explicitly described as the foundation's first-ever HIV/AIDS grant since its 2018 launch — to strengthen community care delivery and supply chain systems serving approximately 605,000 lives in Kenya. Plan International received $690,000 over two years for climate-related disaster preparedness work with indigenous and climate-vulnerable communities in Peru's Loreto region, reaching an estimated 15,000+ community members.

Prior to the 2024 cycle, active multi-year grants included Amref Health Africa ($1.7M over three years for child health in Senegal) and AMPATH Kenya ($1.07M over two years for mental health services in western Kenya), together representing over $2.7M in ongoing commitments.

No 2025 or 2026 grant announcements have been publicly released as of June 2026. At the corporate level, Astellas Pharma issued a five-year strategic plan in early 2025 emphasizing sustainable growth, which may signal continued foundation funding stability through the plan period. The foundation's officer roster across recent 990 filings lists Moyra Knight and subsequently Shingo Iino as President, Angelique Lewis as Vice President, Amy Skarr as Treasurer, and contact listed as Junko Bozenda — all compensation recorded at $0, consistent with a corporate foundation structure in which staff are employed by Astellas Pharma rather than the foundation entity itself.

The single most important piece of advice for organizations seeking Astellas Global Health Foundation funding: do not submit an unsolicited application. The foundation's RFP process is entirely closed — only organizations receiving a formal invitation may apply through the online portal at astellasusafoundation.us. Attempting to submit outside this structure results in immediate disqualification, and the foundation states this policy unambiguously across all public materials.

Build visibility through Astellas Pharma's networks, not the foundation directly. The foundation publishes no contact email or inquiry pathway. However, Astellas Pharma's corporate sustainability and global health teams attend major international health convenings — WHO World Health Assembly, UN General Assembly side events, International AIDS Conference, and neglected tropical disease forums. Presenting at these venues, co-authoring impact research with current grantees, and being visible in the NGO landscape of Astellas's target geographies (Sub-Saharan Africa, South Asia, Latin America) are the realistic pathways to receiving an RFP invitation.

Clear the 15% overhead threshold before any outreach. Administrative costs exceeding 15% of program funds are a hard disqualifying condition — not a negotiating point. Ensure your financial statements clearly document sub-15% overhead before any relationship-building effort. This is especially important for US-headquartered intermediary organizations running international programs.

Speak systems, not services. The foundation's grant language consistently favors 'infrastructure strengthening,' 'systems improvements,' 'supply chain,' and 'training initiatives' over individual patient counts. PATH's $1.6M HIV/AIDS award was framed around strengthening community care delivery systems and supply chain activities — not direct treatment provision. Lead proposals with systemic change at scale.

Match scale expectations. The observable grant range is $345,000 to $1.6 million over 1–3 years. Requests below $300,000 or above $2 million fall outside demonstrated precedent. Three-year grants require rigorous M&E frameworks and annual progress and financial reconciliation reporting.

Leverage existing grantee relationships. Indiana University (AMPATH), Sightsavers, Amref Health Africa, PATH, Americares, and USA for UNHCR are all repeat grantees. Organizations with established consortium memberships or co-implementation arrangements with these institutions may find natural advocacy pathways into the foundation's internal nominee deliberations.